This randomized, double-blind, double-dummy study compared the efficacy and safety of intravenous anidulafungin to that of oral fluconazole in 601 patients with endoscopically and microbiologically documented esophageal candidiasis
We compared anidulafungin with fluconazole in a randomized, double-blind, non-inferiority trial of treatment for invasive candidiasis
Our review demonstrates superior efficacy for anidulafungin vs fluconazole
Anidulafungin also showed better efficacy at EOIT and at 2 weeks after EOIT, and was non-inferior at 6 weeks post-EOIT
This analysis based on prospectively collected data from a pivotal clinical trial confirms that Endoscopic response at end of therapy: anidulafungin 97
We compared anidulafungin with fluconazole in a randomized, double-blind
To the Editor: The study of anidulafungin as compared with fluconazole for invasive candidiasis by Reboli et al
Baseline characteristics
Version 3
8%: 47: Candidemia and invasive candidiasis: Randomized, double-blinded: 261 (245) 200 mg loading, 100 mg daily: Fluconazole 800 mg loading, 400 mg daily: Global response at the end of therapy: anidulafungin 75
ReSTORE was a multicentre, double-blind, double-dummy, randomised phase 3 trial done at 66 tertiary care centres in 15 countries
Methods Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or
Resource use and cost considerations are important in selecting appropriate treatment
2011 We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis
Background: Candida albicans chorioretinitis is the most common cause of endogenous fungal endophthalmitis
Invasive Candida infections have a particularly strong impact on intensive care unit (ICU) patients [], being associated with mortality rates of 30–50% [1,2]
Ampel Fluconazole achieves urine concentrations that are 10–20 times the concentrations in serum and, thus, is the preferred treatment option for symptomatic cystitis [59]
Candida albicans is the most common cause of candidemia and other forms of invasive candidiasis
The echinocandins include anidulafungin, caspofungin, and micafungin and are a relatively new class of antifungal agents that are administered parenterally and are used in therapy or prevention of serious, invasive aspergillosis and candidal infections
Download scientific diagram | Tornado sensitivity analysis of anidulafungin vs